Pixium Vision S.A.

Pixium Vision S.A.

PXMVF
Pixium Vision S.A.US flagOther OTC
1.50
USD
- -
- -
-8.75EPS
-0.17P/E
4.62MMarket Cap
Oct 21Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Lloyd Diamond
Full Time Employees
40
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
74 rue du Faubourg Saint-Antoine Paris France 75012
IPO Date
Jul 16, 2021
Similar Companies
Business
Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.